Skip to main content
. 2021 Apr 22;11:8786. doi: 10.1038/s41598-021-87710-0

Table 2.

Proteins identified to be significantly different in plasma of CKD patients as compared to the healthy control group.

Target CKD relative to healthy Biological pathways
CKD/healthy p value
PSP 2.4 < 0.0001 Cell proliferation and differentiation
Desmocollin 2 2.3 < 0.0001 Cell–cell junctions
Sclerostin 2.2 < 0.0001 Bone formation
Cystatin C 2.2 < 0.0001 Protein degradation
FABPL 2.1 < 0.0001 Fatty acid metabolism
REG4 2.1 < 0.0001 Cell proliferation, generation
tPA 1.9 < 0.0001 Fibrinolysis
IGFBP-6 1.9 < 0.0001 Cell proliferation, angiogenesis
CD59 1.9 < 0.0001 Complement-induced lysis, T cell activation
Ephrin-A4 1.8 < 0.0001 Angiogenesis
EFNB2 1.8 < 0.0001 Angiogenesis
SECTM1 1.8 < 0.0001 Immune response, inflammation
Ephrin-A2 1.8 < 0.0001 Angiogenesis
SMOC1 1.7 < 0.0001 Angiogenesis, fibrosis
Ephrin-A5 1.7 < 0.0001 Angiogenesis
VEGF-D 1.7 < 0.0001 Angiogenesis
PIANP 1.6 < 0.0001 Immune modulation
Endostatin 1.6 < 0.0001 Angiogenesis
MIA 1.6 < 0.0001 Cell proliferation, extracellular matrix
TIMP-1 1.5 < 0.0001 Extracellular matrix
VEGF-A 1.5 < 0.0001 Angiogenesis
NEGR-1 1.3 0.0001 Cell adhesion, axon sprouting

The data are shown ratiometrically for relative fluorescence units (RFU) for CKD/healthy control. CKD: chronic kidney disease, PSP: phosphoserine phosphatase, FABPL: fatty acid-binding protein, liver-type, REG4: regenerating islet-derived protein 4, tPA: tissue plasminogen activator, IGFBP-6: insulin-like growth factor-binding protein, EFN: ephrin, SECTM1: secreted and transmembrane protein 1, Ephrin: Eph family receptor interacting proteins, SMOC1: secreted modular calcium-binding protein 1, VEGF: vascular endothelial growth factor, PIANP: PILR Alpha Associated Neural Protein, MIA: melanoma inhibitory activity, TIMP-1: tissue inhibitor of metalloproteinases, NEGR: neuronal growth regulator.